A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients

Chimeric monoclonal antibody G250 (WX-G250) binds to a cell surface antigen found on >90% of renal cell carcinoma (RCC). A multicentre phase II study was performed to evaluate the safety and efficacy of WX-G250 in metastatic RCC (mRCC) patients. In all, 36 patients with mRCC were included. WX-G25...

Descripción completa

Detalles Bibliográficos
Autores principales: Bleumer, I, Knuth, A, Oosterwijk, E, Hofmann, R, Varga, Z, Lamers, C, Kruit, W, Melchior, S, Mala, C, Ullrich, S, Mulder, P De, Mulders, P F A, Beck, J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2410216/
https://www.ncbi.nlm.nih.gov/pubmed/14997194
http://dx.doi.org/10.1038/sj.bjc.6601617

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2410216/
https://www.ncbi.nlm.nih.gov/pubmed/14997194
http://dx.doi.org/10.1038/sj.bjc.6601617

Ejemplares similares